3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis)

3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis)

Neonatal sepsis remains a preeminent cause of neonatal morbidity and mortality worldwide, particularly among very low birth weight (VLBW, < 1,500 g) and extremely low birth weight (ELBW, < 1,000 g) infants. The clinical presentation of neonatal sepsis is notoriously subtle, non-specific, and rapidly progressive—manifesting as temperature instability (hypothermia or hyperthermia), lethargy, apnea, tachypnea, glucose dysregulation, hemodynamic instability, or feeding intolerance. Board Certified Pediatric Pharmacy Specialists (BCPPS) must navigate the distinct microbiologic etiologies, developmental pharmacokinetics, and strict pharmacologic contraindications unique to this vulnerable patient population.

---

Pathophysiology & Neonatal Immune Vulnerabilities

The neonatal immune system exhibits profound developmental immaturity across both innate and adaptive arms:

1. Impaired Humoral Immunity: Maternally derived immunoglobulin G (IgG) is actively transported across the placenta via neonatal Fc receptors (FcRn) primarily during the third trimester, accelerating after 32 weeks of gestation. Preterm infants born prior to 32 weeks have markedly reduced circulating maternal IgG titers, leaving them highly susceptible to encapsulated bacterial pathogens.
2. Defective Phagocytic Function: Neonatal neutrophils (PMNs) exhibit diminished chemotaxis, rolling, and intracellular bacterial killing. Under septic stress, bone marrow reserves of mature neutrophils deplete rapidly, frequently producing profound neutropenia rather than leukocytosis.
3. Attenuated Complement Cascade: Circulating concentrations of complement components (classical, alternative, and lectin pathways) in neonates are roughly 50% of adult levels, leading to blunted opsonization and lysis of Gram-negative and encapsulated organisms.
4. Immature Mucosal and Skin Barriers: In ELBW infants, the stratum corneum lacks keratinized cornified layers until 2 to 4 weeks of postnatal life, facilitating easy transcutaneous bacterial translocation from medical devices and adhesives.

---

Early-Onset Sepsis (EOS) vs Late-Onset Sepsis (LOS)

Neonatal sepsis is chronologically and microbiologically categorized into two distinct clinical syndromes based on the timing of symptom onset:

---

Microbiology & Pathogen Specifics

Early-Onset Pathogens

• Group B Streptococcus (Streptococcus agalactiae): A Gram-positive diplococcus/chain that colonizes the maternal gastrointestinal and genital tract in 15% to 30% of pregnant women. Universal maternal screening at 36 0/7 to 37 6/7 weeks of gestation and intrapartum antibiotic prophylaxis (IV penicillin G or ampicillin >= 4 hours prior to delivery) have reduced early-onset GBS disease by > 80%. However, GBS remains the leading cause of EOS in term infants.
• Escherichia coli: The predominant cause of EOS in preterm infants (< 37 weeks) and VLBW neonates, associated with high mortality rates (20% to 40%). The K1 capsular antigen strain accounts for up to 80% of neonatal E. coli meningitis. Notably, ampicillin resistance among neonatal E. coli isolates ranges from 60% to 85% in VLBW cohorts, making the companion aminoglycoside critical for empiric coverage.
• Listeria monocytogenes: A facultative intracellular Gram-positive bacillus acquired via ingestion of contaminated maternal food (unpasteurized cheeses, cold deli meats). Listeria displays characteristic "tumbling motility" at 20°C–25°C and causes severe fetal infection, septicemia, granulomatosis infantiseptica (disseminated microabscesses), and meningitis. Critical Clinical Rule: Listeria monocytogenes is intrinsically resistant to all cephalosporins due to low binding affinity to penicillin-binding protein 3 (PBP3). Ampicillin is the drug of choice.

Late-Onset Pathogens

• Coagulase-Negative Staphylococci (CoNS): Primarily Staphylococcus epidermidis, accounting for 50% to 60% of all LOS episodes in VLBW neonates. Pathogenesis centers on biofilm (slime) synthesis on plastic polymer surfaces of peripherally inserted central catheters (PICCs) and umbilical venous catheters (UVCs). While mortality is relatively low (1% to 5%), CoNS bacteremia significantly extends hospitalization and contributes to bronchopulmonary dysplasia (BPD) and white matter brain injury.
• Staphylococcus aureus: Causes rapid, aggressive bacteremia, osteomyelitis, endocarditis, and septic shock. Both methicillin-susceptible (S. aureus [MSSA]) and methicillin-resistant (MRSA) strains require prompt identification; empirical vancomycin is narrowed to oxacillin, nafcillin, or cefazolin once MSSA is confirmed.
• Gram-Negative Enteric Bacilli: Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, and Pseudomonas aeruginosa represent 20% to 30% of LOS cases and carry mortality rates exceeding 25% to 40%. The selection of empiric Gram-negative coverage must reflect institutional NICU antibiograms, specifically evaluating extended-spectrum beta-lactamase (ESBL) and AmpC beta-lactamase prevalence.
• Fungal Pathogens: Candida albicans and Candida parapsilosis (biofilm producer). Preterm infants < 1,000 g exposed to third-generation cephalosporins, carbapenems, systemic steroids, or parenteral lipid emulsions are at the highest risk. Empiric therapy with amphotericin B deoxycholate (1 mg/kg/day) or fluconazole (12 mg/kg loading, then 6 mg/kg/day) should be initiated when blood cultures demonstrate yeast or when an infant with central venous access fails to improve after 48 to 72 hours of broad-spectrum antibacterial coverage.

---

Empiric Antimicrobial Regimens & Synergy

                    Neonatal Sepsis Evaluation & Empiric Regimen Algorithm
                    
                                 [ Clinical Suspicion ]
                                           |
               +---------------------------+---------------------------+
               |                                                       |
      Early-Onset (< 72 hours)                                Late-Onset (>= 72 hours)
               |                                                       |
   [ Maternal / Vertical Flora ]                             [ Nosocomial / Device Flora ]
   GBS, E. coli, Listeria                                    CoNS, S. aureus, GNRs, Candida
               |                                                       |
      +--------+--------+                                     +--------+--------+
      |                 |                                     |                 |
  Bacteremia       Meningitis                             Bacteremia       High-Risk / Shock
      |                 |                                     |                 |
 IV Ampicillin     IV Ampicillin                         IV Vancomycin     IV Vancomycin
 100-150 mg/kg/d   200-300 mg/kg/d                       10-15 mg/kg/dose  10-15 mg/kg/dose
   divided q12h      divided q8h                           (TDM target:      (TDM target:
      +                 +                                 AUC/MIC 400-600)  AUC/MIC 400-600)
 IV Gentamicin     IV Gentamicin                              +                 +
 4-5 mg/kg/dose    4-5 mg/kg/dose                         IV Gentamicin     IV Cefepime
 (Extended-interval TDM: Cmax 8-12, Cmin < 1)             or Amikacin       or Meropenem

The Synergy Principle: Ampicillin + Gentamicin

The combination of ampicillin and gentamicin serves as the worldwide cornerstone for empiric EOS. Ampicillin provides bactericidal activity against Listeria monocytogenes, Enterococcus species, and GBS. Gentamicin covers aerobic Gram-negative bacilli (E. coli). Beyond additive coverage, these agents demonstrate classic bactericidal synergy: ampicillin inhibits bacterial cell wall synthesis (transpeptidation), which disrupts cell wall integrity and facilitates the intracellular penetration of gentamicin to bind the 30S ribosomal subunit, causing irreversible protein synthesis inhibition and rapid bacterial death.

Meningitis Dosing Adjustments

Whenever neonatal meningitis cannot be definitively excluded by lumbar puncture (LP)—or when LP is deferred due to clinical instability—high-dose ampicillin is mandatory:

• Bacteremia dose: 100 to 150 mg/kg/day IV divided every 12 hours (in infants <= 7 days of life).
• Meningitis dose: 200 to 300 mg/kg/day IV divided every 8 hours (<= 7 days of life) or every 6 hours (> 7 days of life).

Rationale: Penicillins cross the blood-brain barrier primarily in the setting of active meningeal inflammation. High serum concentrations are required to drive passive CSF diffusion and maintain CSF drug concentrations well above the minimum bactericidal concentration (MBC) of the pathogen.

---

Absolute Contraindications to Ceftriaxone in Neonates

Ceftriaxone is an exceptional third-generation cephalosporin in older children and adults due to its long half-life and potent pneumococcal and meningococcal coverage. However, ceftriaxone is strictly contraindicated in neonates (<= 28 days of life, and preterm infants up to 44 weeks postmenstrual age) due to three severe, life-threatening pharmacologic mechanisms:

1. Albumin Displacement & Kernicterus

Ceftriaxone exhibits very high protein binding (85% to 95%), primarily to human serum albumin. In neonates, circulating albumin concentrations are reduced, and neonatal albumin has a lower binding affinity for drugs. Furthermore, neonatal unconjugated (indirect) bilirubin levels are physiologically elevated due to high red blood cell turnover and immature hepatic uridine diphosphate glucuronosyltransferase (UGT1A1) enzyme activity. Ceftriaxone competitively displaces unconjugated bilirubin from albumin binding sites, sharply elevating the concentration of unbound (free) bilirubin. Lipophilic free bilirubin easily crosses the porous neonatal blood-brain barrier and precipitates within the basal ganglia, subthalamic nuclei, and auditory pathways, causing acute bilirubin encephalopathy and permanent kernicterus (characterized by choreoathetoid cerebral palsy, upward gaze paralysis, sensorineural hearing loss, and dental dysplasia).

2. Microvascular Calcium-Ceftriaxone Precipitation

Ceftriaxone forms insoluble crystalline salts when combined with calcium ions. In neonates receiving intravenous calcium-containing infusions (including parenteral nutrition [PN] with calcium gluconate, Ringer's lactate, or sterile calcium infusions), ceftriaxone forms dense microcrystalline precipitates in the intravascular space. Autopsy studies confirmed crystalline embolization causing fatal vascular occlusion in the pulmonary and renal microvasculature.

[!CAUTION] FDA Boxed Warning: Ceftriaxone and calcium-containing solutions must NEVER be co-administered to neonates (<= 28 days old) through the same line or through different infusion lines within 48 hours of each other. Even sequential administration through flushed lines has resulted in fatal precipitation due to the prolonged neonatal elimination half-life of ceftriaxone (up to 15–20 hours in preterm infants).

3. Biliary Sludging / Biliary Pseudolithiasis

Approximately 40% of ceftriaxone is eliminated unchanged via the biliary system. High biliary drug concentrations precipitate with calcium into an insoluble calcium-ceftriaxone sludge inside the gallbladder and common bile duct, causing biliary colic, pancreatitis, and cholestatic jaundice.

Safe Neonatal Alternatives: Cefotaxime & Cefepime

• Cefotaxime: Low protein binding (30% to 40%), minimal bilirubin displacement, zero calcium precipitation risk, and cleared primarily by renal excretion and hepatic metabolism to desacetylcefotaxime. Historically preferred for neonatal Gram-negative meningitis (dosed at 100–200 mg/kg/day divided q6–12h based on PNA/PMA).
• Cefepime: A fourth-generation cephalosporin with low protein binding (~20%), no calcium precipitation, and excellent penetration through the blood-brain barrier. Provides potent coverage against Pseudomonas aeruginosa and AmpC beta-lactamase producing Enterobacterales (dosed at 30 mg/kg/dose q12h for bacteremia; 50 mg/kg/dose q8–12h for meningitis).

---

Pharmacokinetics & Therapeutic Drug Monitoring (TDM)

Gentamicin: Extended-Interval Dosing

Neonates exhibit a substantially expanded extracellular fluid (ECF) volume compared to older children and adults. In term and preterm neonates, the volume of distribution ($V_d$) for hydrophilic aminoglycosides is $0.5\text{ to }0.7\text{ L/kg}$ (vs $0.25\text{ to }0.3\text{ L/kg}$ in adults). Consequently, neonates require larger weight-based doses (4 to 5 mg/kg) to achieve effective peak concentrations. Concurrently, immature glomerular filtration rates (GFR) in premature infants markedly prolong the elimination half-life ($t_{1/2} = 6\text{ to }18\text{ hours}$ vs $2\text{ to }3\text{ hours}$ in adults), necessitating extended dosing intervals (every 24, 36, or 48 hours):

Pharmacodynamic Targets:

• Concentration-Dependent Killing: Aminoglycoside bactericidal velocity is governed by the peak-to-MIC ratio ($C_{\max}/\text{MIC}$). The clinical target is $C_{\max}/\text{MIC} \ge 8\text{ to }10$. For typical Gram-negative bacilli with an MIC $\le 1\text{ mcg/mL}$, the target peak concentration is 8 to 12 mcg/mL (drawn 30 minutes after a 30-minute IV infusion).
• Minimizing Nephrotoxicity and Ototoxicity: Aminoglycosides accumulate in renal proximal tubular cells via pinocytosis and in inner ear endolymph/perilymph. Uptake into these compartments is saturable; prolonged exposure to elevated trough concentrations drives cell death and hair cell loss. Extended dosing intervals allow complete clearance, ensuring the trough concentration falls < 1 mcg/mL (ideally < 0.5 mcg/mL) prior to the next scheduled dose.

Vancomycin: AUC24/MIC vs Trough-Only Monitoring

Vancomycin exhibits time-dependent bactericidal activity with a post-antibiotic effect. In pediatric and neonatal medicine, consensus guidelines from the American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS) establish that the primary pharmacokinetic/pharmacodynamic (PK/PD) predictor of vancomycin efficacy is the 24-hour area under the curve to minimum inhibitory concentration ratio (AUC24/MIC):

$\frac{\text{AUC}_{24}}{\text{MIC}} \ge 400\text{ to }600\text{ mg}\cdot\text{h/L}\quad (\text{assuming broth microdilution MIC } \le 1\text{ mg/L})$

Why Trough-Only Monitoring is Obsolete and Harmful:

Historically, clinicians titrated vancomycin to target serum trough concentrations of 15 to 20 mcg/mL. In neonates, achieving a trough of 15–20 mcg/mL frequently produces excessive exposure with an $\text{AUC}{24} > 700\text{ to }800\text{ mg}\cdot\text{h/L}$, directly causing acute kidney injury (AKI). Conversely, neonates can comfortably achieve therapeutic $\text{AUC}{24}$ values of 400 to 600 mg*h/L with trough concentrations between 7 and 12 mcg/mL due to their unique pharmacokinetic clearance characteristics.

Clinical Implementation in the NICU:

1. Empiric Dosing: 10 to 15 mg/kg/dose IV every 8, 12, 18, or 24 hours based on postmenstrual age, postnatal age, and serum creatinine.
2. TDM Strategy: Bayesian estimation software (using validated neonatal population PK models) utilizing a single serum concentration or two PK sampling points: a peak drawn 1 to 2 hours post-infusion (to allow distribution phase completion) and a trough drawn within 30 minutes prior to the subsequent dose. Titrate the daily dose and interval to secure an $\text{AUC}_{24}$ of 400–600 mg*h/L while maintaining trough levels < 15 mcg/mL.